This has an impact on tumour angiogenesis and so tumours resistant to normal bolus doses of chemotherapy may respond to low chronic doses of cytotoxics and with different classes of anti-cancer drugs, such as the combination of low-dose vinblastine chemotherapy and a vascular endothelial growth factor (VEGF) receptor 2 antibody (Klement et al, 2000). Here, VEGFA is linked to neoplasm.